Memory, Roche Rewrite Deal To Support Phase IIa Trial In Schizophrenia Cognitive Impairment Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche agrees to extra milestone payment for nicotinic alpha-7 agonist MEM 3454, but relinquishes rights to PDE4 inhibitor program.